Search Result

Results for "

amplitude

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) GABA Receptor (1) iGluR (2) mAChR (1) Na+/K+ ATPase (1) Neuropeptide Y Receptor (2) PKC (1) Potassium Channel (5) Sodium Channel (1)
By Research Areas:	Cardiovascular Disease (9) Infection (1) Neurological Disease (11)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124702

ICA-105574	Potassium Channel	Cardiovascular Disease
ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC₅₀ value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2 .

HY-110175

CX614	iGluR	Neurological Disease
CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .

HY-110162

QO 58	Potassium Channel	Neurological Disease
QO 58 is a potent modulator of K(v)7 channels. QO-58 increases the current amplitudes, shifts the voltage-dependent activation curve in a more negative direction and slows the deactivation of K(v)7.2/K(v)7.3 currents. QO-58 has the potential for the research of diseases associated with neuronal hyperexcitability .

HY-108588

NS5806	Potassium Channel	Cardiovascular Disease
NS5806, a potent potassium current activator, increases K_V4.3/KChIP2 peak current amplitudes with an EC₅₀ of 5.3 μM. NS5806 slows K_V4.3 and K_V4.2 current dacay in channel complexes containing KChIP2 .

HY-113673

A-935142	Potassium Channel	Cardiovascular Disease
A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization .

HY-P1716

Neuropeptide DF2	PKC	Neurological Disease
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .

HY-108502

KC 12291 hydrochloride	Sodium Channel	Cardiovascular Disease
KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na ⁺ current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo .

HY-P3777

β-Bag cell peptide	Potassium Channel	Neurological Disease
β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents .

HY-P1249

Neuropeptide SF(mouse,rat)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide SF (mouse,rat) is a potent neuropeptide FF receptor agonist with K_i values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively. Neuropeptide SF increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) .

HY-105651A

Butalamine hydrochloride	Others	Cardiovascular Disease
Butalamine (hydrochloride) is a peripheral vasodilator with local anesthetic effects. :Butalamine (hydrochloride) can produce in animals coronary vasodilation, local anaesthesia, analgesia and a papaverine like action in duodenal preparations. Butalamine (hydrochloride) causes a slowing in rate of spontaneous activity, a decrease in amplitude and a reduction in isolated human smooth muscle .

HY-135026

DL-Norepinephrine tartrate	Adrenergic Receptor	Neurological Disease
DL-Norepinephrine tartrate is a neurotransmitter, which targets adrenergic receptors, and causes large-amplitude sleep-like electrical activity in the neocortex and suppresses electroencephalography (EEG) activity in the hippocampus. DL-Norepinephrine tartrate results in head shake, difficulty walking, and frequent posture changes in rats model .

HY-P1249A

Neuropeptide SF(mouse,rat) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide SF (mouse,rat) TFA is a potent neuropeptide FF receptor agonist with K_i values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively. Neuropeptide SF TFA increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) .

HY-N8472

Chrodrimanin B	GABA Receptor	Infection
Chrodrimanin B, a metabolite of a fungal, is a potent, non-open-channel-blocking antagonist on?B.?mori GABAR RDL with an IC₅₀?of 1.13 nM. Chrodrimanin B attenuates the peak current amplitude of the GABA response of RDL with an IC₅₀?of 1.66 nM.?Chrodrimanin B, a meroterpenoid, shows insecticidal activity .

HY-15718B

Istaroxime oxalate PST2744 oxalate	Na+/K+ ATPase	Cardiovascular Disease
Istaroxime oxalate (PST2744 oxalate) is the oxalate form of Istaroxime (HY-15718). Istaroxime oxalate is is an inotropic agent, that inhibits Na ⁺/K ⁺-ATPase with an IC₅₀ of 0.11 μM. Istaroxime oxalate increases force of contraction in guinea pig atria and twitch amplitude in isolated guinea pig myocytes without causing lethal arrhythmias .

HY-105651AR

Butalamine (hydrochloride) (Standard)	Others	Cardiovascular Disease
Butalamine (hydrochloride) (Standard) is the analytical standard of Butalamine (hydrochloride). This product is intended for research and analytical applications. Butalamine (hydrochloride) is a peripheral vasodilator with local anesthetic effects. :Butalamine (hydrochloride) can produce in animals coronary vasodilation, local anaesthesia, analgesia and a papaverine like action in duodenal preparations. Butalamine (hydrochloride) causes a slowing in rate of spontaneous activity, a decrease in amplitude and a reduction in isolated human smooth muscle .

HY-B1789

Telenzepine	mAChR	Neurological Disease
Telenzepine is an antimuscarinic agent with Kis of 0.94 nM (M1 mAChR) and 17.8 nM (M2 mAChR) binding to muscarinic receptors. Telenzepine effectively blocks synaptic transmission promoted by muscarinic or M1 receptor agonists. Thus, Telenzepine can reduce the amplitude of extracellular slow excitatory postsynaptic potentials (EC50=38 nM) and slow inhibitory postsynaptic potentials (EC50=253 nM) .

HY-13527

LY310762 1 Publications Verification	5-HT Receptor	Cardiovascular Disease Neurological Disease
LY310762 is a selective 5-HT_1D receptor antagonist (K_i=249 nM) with a weak affinity for 5-HT_1B receptor. LY310762 effectively abolishes the renal vasodilatory effects of *5-HTSumatriptan (HY-B0121B)-induced decrease in excitatory postsynaptic potential (EPSC) amplitude* .**

HY-107719

D-AP7	iGluR	Neurological Disease
D-AP7 is a specific NMDA receptor antagonist with inhibitory activity against epileptiform activity. D-AP7 attenuated neuronal activation in spot activity by reducing the duration and number of exogenously induced bursts. D-AP7 also increased the amplitude of secondary action potentials, which may restore neuronal activity in some epileptiform bursts. D-AP7 showed anxiogenic effects and impaired memory consolidation in passive avoidance learning .

HY-136677

Lnd 796	Others	Cardiovascular Disease
LND 796 is an aminosteroidal derivative with positive inotropic effects similar to those of digitalis. It exhibits electrophysiological, toxic, and inotropic effects in normal and partially potassium-depolarized ventricular muscles. LND 796 requires higher concentrations than digoxin to induce the same toxic symptoms. It exhibits a concentration-dependent positive inotropic effect on guinea pig papillary muscles in normal potassium solution. In partially potassium-depolarized papillary muscles, LND 796 enhances both components of contraction and increases the amplitude of slow action potentials. The mechanism of positive inotropic action of LND 796 involves enhanced calcium entry in calcium channels and inhibition of sodium-potassium ATPase. Due to its expanded positive inotropic range, LND 796 may have potential application in the treatment of congestive heart failure.

Cat. No.	Product Name	Target	Research Area

HY-P4182

Schistoflrfamide	Peptides	Neurological Disease
Schistoflrfamide, a FMRFamide-related peptide, is an inhibitory neuropeptide. Schistoflrfamide decreases the amplitude and frequency of myogenic contractions and reduce basal tension visceral muscle .

HY-P2590

Tnrnflrfamide	Peptides	Others
Tnrnflrfamide is a neuropeptide that modulates the receptor muscles of the lobster abdominal stretch receptors and their exoskeletal muscle homologues. Tnrnflrfamide enhances motor performance, including the amplitude of excitatory postsynaptic potentials and the development of nerve-evoked tension .

HY-P1716

Neuropeptide DF2	PKC	Neurological Disease
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .

HY-P3777

β-Bag cell peptide	Potassium Channel	Neurological Disease
β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents .

HY-P1249

Neuropeptide SF(mouse,rat)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide SF (mouse,rat) is a potent neuropeptide FF receptor agonist with K_i values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively. Neuropeptide SF increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) .

HY-P1249A

Neuropeptide SF(mouse,rat) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide SF (mouse,rat) TFA is a potent neuropeptide FF receptor agonist with K_i values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively. Neuropeptide SF TFA increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) .

Chrodrimanin B	Infection Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	GABA Receptor
Chrodrimanin B, a metabolite of a fungal, is a potent, non-open-channel-blocking antagonist on?B.?mori GABAR RDL with an IC₅₀?of 1.13 nM. Chrodrimanin B attenuates the peak current amplitude of the GABA response of RDL with an IC₅₀?of 1.66 nM.?Chrodrimanin B, a meroterpenoid, shows insecticidal activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

amplitude

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products